• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Malaysia·Healthcare·7148.KL
Share

Duopharma Biotech Berhad Stocks

MYR 1.21Last Updated 23.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

MYR 283.89M

MYR 1.21
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 7148.KL is 1.6 and suggests 31.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 18:15

Gold fell below $4,000—for the first time since November. Is the precious metal's rally over?

24.06.2026 17:39

The next two years will show which AI companies investors should have avoided — Jim Chanos

24.06.2026 17:14

Trump said he had received a promise from Iran not to charge fees in the Strait of Hormuz. Brent is below $75

24.06.2026 16:50

Samsung is rebounding after a sell-off: the company announced a $59 billion buyback

24.06.2026 16:29

"Gold's appeal as a safe haven is waning": the price has fallen below $4,100

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026